GLP-1 medicines and pregnancy — what the label says

Can I take Wegovy while trying to get pregnant?

Current UK labelling for semaglutide-based products, including semaglutide (Wegovy, Ozempic), advises against use during pregnancy. The SmPC further recommends stopping treatment before actively trying to conceive, reflecting a precautionary approach based on limited human pregnancy exposure data combined with findings from animal reproductive toxicity studies. This is a labelling position, not a description of demonstrated human harm — the distinction matters when interpreting what the evidence does and does not show.

What does the Wegovy label say about pregnancy?

The Wegovy SmPC states that the medicine is not recommended during pregnancy because data in pregnant women are insufficient to establish whether there is a risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Animal studies have shown reproductive toxicity at doses associated with the pharmacological effect (reduced maternal food intake and bodyweight), and regulators have applied a precautionary class approach as a result. Women of childbearing potential are advised in the labelling to use effective contraception while on treatment.

How long before conception should I stop a GLP-1 medicine?

Labelling for semaglutide-based products recommends discontinuing treatment at least two months before a planned pregnancy. This window is derived from the elimination half-life of semaglutide — approximately one week — meaning several half-lives are needed for the medicine to clear the body to a level considered acceptable ahead of conception. For tirzepatide (Mounjaro), which has a broadly comparable half-life, product labelling contains an analogous discontinuation recommendation. Exact windows and wording differ by product and jurisdiction, so the current SmPC for the specific medicine is the definitive reference, and timing should be planned together with the prescriber managing treatment.

What is the pharmacovigilance signal on unintended pregnancy exposure?

As GLP-1 prescribing volumes have grown, regulators including the MHRA and EMA have received post-marketing reports of pregnancies occurring in women taking these medicines, including some conceived while on treatment. Part of the interest in this signal relates to a theoretical interaction between GLP-1 pharmacology — delayed gastric emptying — and oral contraceptive absorption, particularly where gastrointestinal side effects such as vomiting or diarrhoea are also present. Pregnancy exposure registries and post-marketing surveillance are ongoing mechanisms for building a clearer picture of outcomes; current data are not yet sufficient to characterise a specific risk pattern with confidence, which is itself the reason for the continued precautionary labelling.

Why might GLP-1 medicines interact with oral contraceptives?

Delayed gastric emptying is an on-target pharmacological effect of GLP-1 receptor activation, not a side effect distinct from how the medicine works. Slower transit combined with gastrointestinal adverse events such as vomiting has raised a theoretical concern that oral medicines, including contraceptive pills, could be absorbed less reliably during GLP-1 therapy. Some product labelling — notably for oral semaglutide (Rybelsus) — references contraceptive considerations directly, given the additional variable of co-administration with an oral GLP-1 formulation. This is a labelling caution rather than a confirmed reduction in contraceptive efficacy across the class, and anyone relying on oral contraception during GLP-1 therapy should discuss suitable contraceptive strategy with their prescriber or a sexual health clinician.

What about breastfeeding?

SmPCs for licensed GLP-1 medicines generally advise against use while breastfeeding, on the basis that it is not known whether these medicines, or their metabolites, are excreted in human breast milk, and a risk to the breastfed infant cannot be excluded from available data. As with the pregnancy precaution, this reflects an absence of adequate human lactation data rather than a demonstrated harm to breastfed infants.

Are the labels the same across Ozempic, Wegovy, Mounjaro and Saxenda?

The broad precautionary approach — avoid in pregnancy, discontinue ahead of planned conception, avoid while breastfeeding — is consistent across licensed GLP-1 receptor agonists and dual incretin agonists in the UK, because it stems from a class-wide shortage of adequate human pregnancy and lactation data rather than a finding specific to one molecule. Discontinuation windows differ slightly based on each molecule's half-life: liraglutide (Saxenda, Victoza) has a shorter half-life than semaglutide or tirzepatide, which is reflected in its own discontinuation guidance. The current SmPC for the specific product prescribed is the authoritative source, and product labelling is periodically updated as new pharmacovigilance data accumulate.

Frequently asked questions

Can I take Wegovy while trying to get pregnant?

The Wegovy (semaglutide) SmPC advises against use during pregnancy and recommends discontinuation before a planned pregnancy, based on the discontinuation window described in the product information. This is a labelling position based on limited human pregnancy data and reproductive toxicity findings in animal studies, not a demonstrated harm in humans. Anyone planning conception while on a GLP-1 medicine should discuss timing directly with their prescriber.

What does the Wegovy label say about pregnancy?

The SmPC states that semaglutide should not be used during pregnancy because human data are insufficient to establish safety, and animal reproductive toxicity studies have shown effects on embryo-fetal development. The label recommends that women of childbearing potential use contraception while on treatment.

How long before conception should I stop a GLP-1 medicine?

Product labelling for semaglutide-based medicines (Wegovy, Ozempic, Rybelsus) recommends discontinuing at least two months before a planned pregnancy, reflecting the long elimination half-life of semaglutide (approximately one week, meaning several weeks are needed to clear the medicine). This is a labelling recommendation, not individual clinical advice — timing should be agreed with the prescriber managing your care.

Does the same two-month rule apply to Mounjaro?

Tirzepatide (Mounjaro) has a similarly long half-life to semaglutide, and its SmPC contains a comparable discontinuation recommendation before planned pregnancy. Exact wording differs slightly by product and by regulator; the current SmPC for each product is the definitive source and should be checked directly, ideally with a prescriber.

What is the pharmacovigilance signal on unintended pregnancy exposure?

Regulators have received post-marketing reports of pregnancies occurring during GLP-1 treatment, sometimes linked to reduced efficacy of oral contraceptives during rapid weight loss and gastrointestinal side effects such as vomiting or diarrhoea. The MHRA and EMA continue to monitor outcomes data from these exposures through pharmacovigilance registries as they mature. Current data are not sufficient to establish or exclude a specific pattern of fetal risk.

Why might GLP-1 medicines interact with oral contraceptives?

Delayed gastric emptying — an on-target pharmacological effect of GLP-1 receptor agonists — combined with gastrointestinal side effects such as vomiting, has raised a theoretical concern about reduced absorption and effectiveness of oral contraceptive pills. Regulators have not issued a uniform class-wide restriction, but some product labelling for oral semaglutide (Rybelsus) specifically references contraceptive considerations. Barrier or non-oral contraceptive methods are a discussion point for anyone relying on oral contraception while on therapy.

What about breastfeeding?

Current SmPCs generally advise against use during breastfeeding because it is unknown whether GLP-1 receptor agonists are excreted in human breast milk, and a risk to the breastfed infant cannot be excluded based on available data. This is a precautionary labelling position reflecting a lack of human lactation data, not a confirmed finding of harm.

Are the labels the same across Ozempic, Wegovy, Mounjaro and Saxenda?

The underlying precautionary principle — avoid use in pregnancy, discontinue before planned conception, avoid during breastfeeding — is broadly consistent across licensed GLP-1 and dual-incretin products, because it reflects a class-level absence of adequate human pregnancy data rather than a molecule-specific finding. However, exact discontinuation windows and specific wording vary by product and by molecule half-life. The current SmPC for the specific product is the authoritative source.

Can I resume a GLP-1 medicine after giving birth?

Resumption after childbirth is a clinical decision that depends on breastfeeding status, the original indication for the medicine, and individual health factors. This is a matter for direct discussion with the prescriber managing postpartum care — this page does not provide a resumption timeline.

Does this mean GLP-1 medicines cause birth defects?

No. Current labelling reflects an absence of sufficient human data to confirm safety, combined with signals from animal reproductive toxicity studies, rather than a confirmed finding of teratogenicity in humans. Precautionary labelling and demonstrated harm are not the same thing. Ongoing pregnancy exposure registries are intended to build the human evidence base over time.